Regulus Therapeutics Inc

NASDAQ RGLS

Download Data

Regulus Therapeutics Inc Price to Sales Ratio (P/S) on June 03, 2024: 479.07

Regulus Therapeutics Inc Price to Sales Ratio (P/S) is 479.07 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.
  • Regulus Therapeutics Inc 52-week high Price to Sales Ratio (P/S) is 526.76 on May 06, 2024, which is 9.95% above the current Price to Sales Ratio (P/S).
  • Regulus Therapeutics Inc 52-week low Price to Sales Ratio (P/S) is 409.70 on May 21, 2024, which is -14.48% below the current Price to Sales Ratio (P/S).
  • Regulus Therapeutics Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 458.52.
NASDAQ: RGLS

Regulus Therapeutics Inc

CEO Mr. Joseph P. Hagan M.B.A.
IPO Date Oct. 4, 2012
Location United States
Headquarters 4224 Campus Point Court, San Diego, CA, United States, 92121
Employees 30
Sector Healthcare
Industry Biotechnology
Description

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Similar companies

VSTM

Verastem Inc

NA

NA

PULM

Pulmatrix Inc

NA

NA

CLRB

Cellectar Biosciences Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email